All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · represents biopharmaceutical research companies

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 19, 2025

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

STEPHEN THOMAS VOLJAVEC New on this filing

Previously held: Legislative Director, Rep. Vern Buchanan; Legislative Assistant, Senator Marsha Blackburn

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 10

S 891
Bipartisan Health Care Act
S 527
Prescription Pricing for the People Act of 2025
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
S 1097
Interagency Patent Coordination and Improvement Act of 2025
S 1095
Stop STALLING Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 5

Health Issues

340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance; insulin price cap; PBM reform; TRICARE Pharmacy Program (FY2026 National Defense Authorization Act); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1492/S.832, EPIC Act of 2025.

Budget/Appropriations

H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.